Arabinogalactan-folic acid-drug conjugate for targeted delivery and target-activated release of anticancer drugs to folate receptor-overexpressing cells

Biomacromolecules

Volumn 11, Issue 1, 2010, Pages 294-303

  Pinhassi, Roy I ^a   Assaraf, Yehuda G ^a   Farber, Shimon ^b   Stark, Michal ^a   Ickowicz, Diana ^b   Drori, Stavit ^a   Domb, Abraham J ^b   Livney, Yoav D ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-TUMOR AGENTS; ANTICANCER DRUG; ARABINOGALACTAN; CANCER CELLS; CELLULAR UPTAKE; CLINICAL TRIAL; CYTOTOXIC; CYTOTOXIC ACTIVITIES; DRUG-CONJUGATES; EPITHELIAL CELLS; FOLATE RECEPTOR; FOLATES; FOLIC ACIDS; HIGH AFFINITY LIGANDS; NANOCONJUGATES; NATURAL POLYSACCHARIDE; RECEPTOR-MEDIATED ENDOCYTOSIS; RELEASE MECHANISM; TARGETED DELIVERY; THERAPEUTIC AGENTS; WATER SOLUBILITIES;

CELLS; ORGANIC ACIDS;

TARGETS;

ARABINOGALACTAN; FOLATE RECEPTOR; FOLIC ACID; METHOTREXATE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; ULTRAVIOLET SPECTROSCOPY;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARRIER PROTEINS; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; FOLIC ACID; GALACTANS; HUMANS; METHOTREXATE; RECEPTORS, CELL SURFACE;

EID: 73949115139     PISSN: 15257797     EISSN: None     Source Type: Journal    
DOI: 10.1021/bm900853z     Document Type: Article

References (39)

1. Assaraf, Y. Cancer Metastasis Rev. 2007, 26, 153-181.
2. Sinha, R.; Kim, G. J.; Nie, S. M.; Shin, D. M. Mol. Cancer Ther. 2006, 5, 1909-1917.
3. Brannon-Peppas, L.; Blanchette, J. O. Adv. Drug Delivery Rev. 2004, 56, 1649-1659.
4. Dyba, M.; Tarasova, N. I.; Michejda, C. J. Curr. Pharm. Des. 2004, 10, 2311-2334.
5. Kumar, A.; Srivastava, A.; Galaev, I. Y.; Mattiasson, B. Prog. Polym. Sci. 2007, 32, 1205-1237.
6. Duncan, R. Nat. Rev. Cancer 2006, 6, 688-701.
7. Haag, R.; Kratz, F. Angew. Chem., Int. Ed. 2006, 45, 1198-1215.
8. Zhang, J.; Lan, C. Q.; Post, M.; Simard, B.; Deslandes, Y.; Hsieh, T. H. Cancer Genomics Proteomics 2006, 3, 147-157.
9. Freiberg, S.; Zhu, X. X Int. J. Pharm. 2004, 282, 1-18.
10. Satchi-Fainaro, R.; Duncan, R.; Barnes, C. M. Adv. Polym. Sci. 2006, 193, 1-65.
11. Vicent, M. J.; Duncan, R. Trends Biotechnol. 2006, 24, 39-47.
12. Watanabe, J.; Iwamoto, S.; Ichikawa, S. Colloids Surf., B 2005, 42, 141-146.
13. Zhang, H.; Mardyani, S.; Chan, W. C. W.; Kumacheva, E. Biomacromolecules 2006, 7, 1568-1572.
14. Emanuel, N.; Kedar, E.; Bolotin, E. M.; Smorodinsky, N. I.; Barenholz, Y. Pharm. Res. 1996, 13, 861-868.
15. Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz, Y. Cancer Res. 1994, 54, 987-992.
16. Falk, R.; Domb, A. J.; Polacheck, I. Antimicrob. Agents Chemother. 1999, 43, 1975-1981.
17. Duncan, R. Nat. Rev. Drug Discovery 2003, 2, 347-360.
18. Leamon, C. P. Curr. Opin. Invest. Drugs 2008, 9, 1277-1286.
19. Leamon, C. P.; Jackman, A. L. Vitam. Horm. 2008, 79, 203-233.
20. Wang, S.; Low, P. S. J. Controlled Release 1998, 53, 39-48.
21. Leamon, C. P.; Low, P. S. Biochem. J. 1993, 291 (Pt 3), 855-860.
22. Shia, J.; Klimstra, D. S.; Nitzkorski, J. R.; Low, P. S.; Gonen, M.; Landmann, R.; Weiser, M. R.; Franklin, W. A.; Prendergast, F. G.; Murphy, L.; Tang, L. H.; Temple, L.; Guillem, J. G.; Wong, W. D.; Paty, P. B. Hum. Pathol. 2008, 39, 498-505.
23. Leamon, C. P.; Reddy, J. A. Adv. Drug Deliery Rev. 2004, 56, 1127-1141.
24. Lee, R. J.; Low, P. S. Biochim. Biophys. Acta, Biomembr. 1995, 1233, 134-144.
25. Wang, S.; Low, P. S. J. Controlled Release 1998, 53, 39-48.
26. Goren, D.; Horowitz, A. T.; Tzemach, D.; Tarshish, M.; Zalipsky, S.; Gabizon, A. Clin. Cancer Res. 2000, 6, 1949-1957.
27. Leamon, C. P.; Reddy, J. A. Adv. Drug Delivery Rev. 2004, 56, 1127-1141.
28. Salazar, M.; Ratnam, M. Cancer Metastasis Rev. 2007, 26, 141-152.
29. Russell-Jones, G.; McTavish, K.; McEwan, J.; Rice, J.; Nowotnik, D. J. Inorg. Biochem. 2004, 98, 1625-1633.
30. Rejmanova, P.; Kopecek, J.; Duncan, R.; Lloyd, J. B. Biomaterials 1985, 6, 45-48.
31. Zhao, H.; Heindel, N. D. Pharm. Res. 1991, 8 (3), 400-402.
32. Rothem, L.; Berman, B.; Stark, M.; Jansen, G.; Assaraf, Y. G. Mol. Pharmacol. 2005, 68, 616-624.
33. Roberts, S. J.; Petropavlovskaja, M.; Chung, K. N.; Knight, C. B.; Elwood, P. C. Arch. Biochem. Biophys. 1998, 351, 227-235.
34. Duncan, R. Nat. Rev. Drug Discovery 2003, 2, 347-360.
35. Gabizon, A.; Horowitz, A. T.; Goren, D.; Tzemach, D.; Mandelbaum-Shavit, F.; Qazen, M. M.; Zalipsky, S. Bioconjugate Chem. 1999, 10, 289-298.
36. Turek, J. J.; Leamon, C. P.; Low, P. S. J. Cell Sci. 1993, 106, 423-430.
37. Leamon, C. P.; Reddy, J. A. Adv. Drug Delivery Rev. 2004, 56, 1127-1141.
38. Lu, Y.; Low, P. S. Adv. Drug Delivery Rev. 2002, 54, 675-693.
39. Assaraf, Y. G. Drug Resist. Updates 2006, 9, 227-246.